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Scientists and clinicians studying a particular disease have an ideal goal that, if achieved, would
be paradoxical: finding the disease cure and thereby putting themselves out of work. 2015
marks the 35th year since the cure for smallpox eradicated this human scourge. Before a vac-
cine was developed, infection with smallpox virus occurred in over 10 million people per year
around the world, with a death rate greater than 30% [1]. The World Health Organization’s
(WHO’s) intensive eradication program against smallpox began in 1967 and was maintained
for over ten years. The last known case of smallpox was recorded in Somalia in 1977, and
WHO declared the global eradication of smallpox a success in 1980. Vaccinia virus (VACV),
like smallpox a member of the Poxviridae family, was used to produce the vaccine that led to
smallpox eradication. Today, VACV remains a critical research tool and serves as the labora-
tory model for poxvirus. VACV is currently used for the production of 2nd- and 3rd-genera-
tion smallpox vaccines as well as for the exploration of immuno-oncolytic therapies against
melanoma and other cancers [2,3]. VACV and its derivatives, including modified vaccinia
virus (MVA) and New York attenuated vaccinia virus (NYVAC), are used as vectors by which
to induce immunity to pathogens including HIV, Plasmodium falciparum, andMycobacterium
tuberculosis [4,5]. VACV also continues to be an important tool for examining fundamental
viral mechanisms of immune evasion, including viral immunomodulation and inhibition of
cell apoptosis, and has aided investigators in characterizing the innate and adaptive host
immune response to viral infection [6]. Therefore, despite the eradication of human disease
caused by smallpox virus, basic and applied research using the model vaccinia virus continues
to guide our understanding of host immune responses, antigen immunogenicity, viral manipu-
lation of host defenses, and vaccine efficacy.
A second infectious pathogen that is targeted for eradication is Dracunculus medinensis, or
guinea worm, the nematode parasite that causes drancunculiasis. D.medinensis is contracted
by drinking larvae-contaminated water. The parasite matures to an adult worm in the host gut
and emerges painfully months later through the skin of the lower extremities. Through efforts
of the World Health Assembly (as part of WHO), the Carter Center, and other organizations,
dracunculiasis is nearing worldwide eradication. In the 1980s, 20 endemic countries accounted
for 3.5 million cases of dracunculiasis; by 2014, only 126 cases were reported in four countires:
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Chad, Ethiopia, Mali, and South Sudan [7,8]. Despite being close to eradicating D.medinensis,
we continue to use this parasite to understand endosymbiotic relationships in organisms.Wol-
bachia, a bacterial symbiont found in many filarial nematodes and necessary for worm survival,
are absent in D.medinensis [9]. Understanding why most filarial nematodes requireWolba-
chia, through comparative laboratory-based studies of Drancunculus, may inform endosymbi-
ont-targeted efforts to eradicate other filarial parasites. Thus, we contend that there is an
important scientific role for maintenance of selected pathogens that have otherwise been eradi-
cated, or nearly eradicated, outside the laboratory setting.
Like dracunculiasis, schistosomiasis is a tropical disease caused by a parasitic worm. This
snail-borne disease is deeply tied to modifiable environmental conditions (i.e., bodies of water
conducive to snail survival), a feature which has, in large part, led to calls to set an agenda for
schistosomiasis elimination [10]. Schistosomes are spread by freshwater snails when the larval
form of schistosomes, the cercariae, emerges from infected snails and penetrates the skin of its
human host, taking up residence in blood vessels following maturation to adult worms. The
adult worms produce hundreds of eggs per day, some exiting the host in the urine and/or feces,
contributing to the pernicious cycle of environmental contamination and reinfection in people.
However, many of the eggs become trapped in host tissues including the liver, intestine, and
bladder. The damage caused by chronic parasite egg deposition is significant and contributes
to the high morbidity and mortality observed in schistosomiasis. Schistosome infection pres-
ents unique challenges to worldwide eradication goals and has even proven difficult to elimi-
nate from a targeted endemic region. If eradication of schistosomiasis were achieved, however,
the benefits of schistosomiasis research would remain. In fact, the study of schistosomes, schis-
tosomiasis pathogenesis, and immunological characterizations of the host response to parasite
egg antigen are currently large areas of study that have been driven by use of schistosomes as a
model organism to study stem cell biology, acute and chronic inflammation, liver and gut
fibrosis, and T helper 2-type responses, among many others. These and other research objec-
tives will remain a focus of study for many scientists and clinicians, independently of a “cure”
for schistosomiasis.
For example, it has long been observed that schistosomes persist for years to decades in the
blood vessels of humans. This successful parasitism underscores Schistosoma species’ aptitude
for host immune evasion and longevity. In recognition of this interesting property of Schisto-
soma worms, planaria scientists have begun adapting their versatile toolbox to schistosomes,
also a flatworm of the phylum Platyhelminthes. Collins et al. [11] have characterized a prolifer-
ating somatic cell (PSC) population in adult worms that may contribute to the ability of schis-
tosomes to repair injury and resist senescence. Studying the stem cell biology of long-lived
metazoans may reveal pathways relevant to human aging.
Schistosomes have also proven to be powerful tools by which some of the earliest delinea-
tion of the TH1 versus TH2 immunity paradigm was shaped [12], with implications for immu-
nological pathway discovery across many diseases. Infection with pathogens that induce TH1
CD4+ lymphocytes and secrete interferon gamma (IFNg) and interleukin-2 (IL-2) can be com-
pared to induction of the TH2 response following schistosome infection or exposure to parasite
eggs or egg antigen resulting in the production of IL-4, IL-5, and IL-13. In addition, the mouse
model of Schistosoma mansoni infection has helped characterize the role of IL-10 as an anti-
inflammatory cytokine required to control liver pathology following egg deposition and, more
broadly, has helped define IL-10 immunoregulation in other diseases in which inflammation
drives pathology, including ulcerative colitis, Crohn’s disease, and, in the lung, allergy and
asthma. In addition to schistosomiasis, IL-10 helps control the immunopathogenesis observed
following infection with Plasmodium spp.,Mycobacterium spp., and Trypanosoma cruzi.
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Several investigators have taken advantage of the strong immunogenic properties and ease
of use of S.mansoni parasite eggs and soluble egg antigens (SEA). Graham et al. [13] have mod-
eled pulmonary hypertension following intravenous injection of Schistosoma eggs and showed
that vascular endothelial growth factor (VEGF) contributes to the TH2 environment that sup-
ports airway remodeling and vascular inflammation. SEA has also been utilized as an adjuvant
to boost a cytotoxic lymphocyte population following vaccination with an HIV-1 Gag con-
struct [14].
Last, and not least, we introduce Schistosoma haematobium to dissect the link between
inflammation and cancer. The International Agency for Research in Cancer (IARC) of WHO
has declared S. haematobium to be a class I carcinogen for the bladder, "definitely carcinogenic
for humans" [15]. Despite the strong link between S. haematobium, the causative agent of uro-
genital schistosomiasis, and bladder carcinogenesis, we understand very little regarding how
this helminth causes cancer. Most hypotheses suggest that S. haematobium-induced chronic
inflammation is critical in the oncogenic process. Interestingly, S. haematobium is linked to
higher rates of squamous cell carcinoma of the bladder, a form of bladder cancer that is
unusual in non-S. haematobium-infected patients. Our inadequate knowledge of schistosomal
bladder carcinogenesis underscores the importance of tractable animal models of urogenital
schistosomiasis [16–23]. These models have identified potential mediators of fibrosis, immu-
nomodulation, and carcinogenesis that may be common to multiple neoplasms. Given the evi-
dence that urogenital schistosomiasis-induced bladder cancer is an inflammatory process,
studying schistosomiasis, even if eradicated, may reveal new links between inflammation and
carcinogenesis that are suitable as therapeutic targets in non-schistosomal cancers. Thus, pru-
dent laboratory maintenance and study of particular pathogens that have been globally elimi-
nated or eradicated may yield unique scientific discoveries of broad significance.
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